Company profile

Ticker
ABBV
Exchange
CEO
Richard A. Gonzalez
Employees
Incorporated in
Location
Fiscal year end
SEC CIK
IRS number
320375147

ABBV stock data

(
)

Fund data

Data from SEC filings
Amount sold
Number of investors

Calendar

5 Aug 19
23 Oct 19
31 Dec 19

News

Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue 8.26B 7.83B 8.31B 8.24B
Net income 741M 2.46B -1.83B 2.75B
Diluted EPS 0.49 1.65 -1.23 1.81
Net profit margin 8.98% 31.37% -21.99% 33.35%
Operating income 3.4B 3.01B -2.44B 3.16B
Net change in cash 275M -2.39B -726M 4.47B
Cash on hand 5.17B 4.9B 7.29B 8.02B
Cost of revenue 1.82B 1.69B 2.02B 1.84B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 32.75B 28.22B 25.64B 22.86B
Net income 5.69B 5.31B 5.95B 5.14B
Diluted EPS 3.66 3.3 3.63 3.13
Net profit margin 17.36% 18.82% 23.22% 22.50%
Operating income 6.38B 9.55B 9.34B 7.54B
Net change in cash -2.01B 4.2B -3.3B 51M
Cash on hand 7.29B 9.3B 5.1B 8.4B
Cost of revenue 7.72B 7.04B 5.83B 4.5B

Financial data from AbbVie earnings reports

Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: abnormality, acetate, adenosine, Allergan, amended, Amendment, amplification, antibody, Appendix, Bank, BBB, biologic, biomarker, bleeding, branded, breast, bridge, CANOVA, carboplatin, CFR, commonly, consummation, contemplated, criteria, daily, delay, depatuxizumab, device, drawn, duly, EGFR, epidermal, event, exhibit, eye, formatted, Foundation, furnished, futility, germline, glioblastoma, GOG, halted, heavy, hereto, herewith, impose, Inline, Investor, issuer, iXBRL, jeopardize, JPMorgan, jurisdictional, lack, Language, leader, lifted, mafodotin, menstrual, MM, Moody, Morgan, negative, negatively, notch, outlined, outlook, ovarian, paclitaxel, palsy, PARP, pattern, poly, polymerase, progressive, prolonged, protocol, radiation, recommended, regenerative, Section, showed, Stanley, SubsidiariesCondensed, supranuclear, surgical, survival, temozolomide, thereto, thereunto, timeframe, timeline, tranche, translocation, undersigned, VELIA, veliparib
Removed: affiliated, appellate, breakthrough, Chancery, designation, eleven, fixed, Fournier, improvement, Industrie, led, Louisiana, principle, proceeding, reached, reinstatement, Sante, sNDA, sought, transfer, TriCor, unspecified

Patents

APP
Utility
ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
17 Oct 19
The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
APP
Utility
Therapeutic DLL4 Binding Proteins
17 Oct 19
DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity.
APP
Utility
Apoptosis-inducing Agents for the Treatment of Cancer and Immune and Autoimmune Diseases
17 Oct 19
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
APP
Utility
Processes for the Preparation of (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-A]PYRROLO[2,3-E]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE and Solid State Forms Thereof
17 Oct 19
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
GRANT
Utility
Synthetic route to anti-viral agents
15 Oct 19
The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.